会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Tat-derived transport polypeptides and fusion proteins
    • Tat衍生的转运多肽和融合蛋白
    • US5804604A
    • 1998-09-08
    • US450236
    • 1995-05-25
    • Alan FrankelCarl PaboJames G. BarsoumStephen E. FawellR. Blake Pepinsky
    • Alan FrankelCarl PaboJames G. BarsoumStephen E. FawellR. Blake Pepinsky
    • A61K47/48C07K14/16C12N15/87C07K7/06C07K7/08C07K14/155C07K19/00
    • C07K14/005A61K47/48238C12N15/87C07K2319/10C07K2319/55C07K2319/71C07K2319/80C12N2740/16322
    • This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation. The reduced size of the preferred transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.
    • 本发明涉及生物活性物质分子如多肽和核酸在体外和体内递送到细胞的细胞质和细胞核中。 根据本发明的货物分子的细胞内递送通过使用包含HIV tat蛋白或其一个或多个部分并且共价连接到货物分子的新型转运多肽来实现。 本发明优选实施方案中的转运多肽的特征在于存在tat碱性区(氨基酸49-57),不存在富含半胱氨酸的区域(氨基酸22-36)和不存在tat外显子 2编码的天然存在的tat蛋白的羧基末端结构域(氨基酸73-86)。 由于缺乏富含半胱氨酸的区域,本发明优选的转运多肽解决了假反式激活和二硫键聚集的潜在问题。 本发明优选的转运多肽的减小的尺寸还使对货物分子的生物活性的干扰最小化。